Nuclear accumulation of polyglutamine disease proteins and neuropathology

Molecular Brain

Volumn 2, Issue 1, 2009, Pages

  Havel, Lauren S ^a   Li, Shihua ^a   Li, Xiao Jiang ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ATAXIN 1; ATAXIN 2; ATAXIN 3; ATAXIN 6; ATAXIN 7; ATROPHIN 1; HUNTINGTIN; MUTANT PROTEIN; POLYGLUTAMINE; PROTEIN; UNCLASSIFIED DRUG; PEPTIDE;

BRAIN; BRAIN STEM; CELL NUCLEUS; CELLULAR DISTRIBUTION; CENTRAL NERVOUS SYSTEM; CEREBELLUM; DEGENERATIVE DISEASE; DENTATORUBROPALLIDOLUYSIAN ATROPHY; DRUG TARGETING; HUMAN; HUNTINGTON CHOREA; KENNEDY DISEASE; MOTONEURON; NEUROLOGIC DISEASE; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PURKINJE CELL; REVIEW; SPINAL CORD; SPINAL MUSCULAR ATROPHY; SPINOCEREBELLAR DEGENERATION; ANIMAL; METABOLISM; PATHOLOGY; TRINUCLEOTIDE REPEAT;

ANIMALS; CELL NUCLEUS; HUMANS; MUTANT PROTEINS; NEURODEGENERATIVE DISEASES; PEPTIDES; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 68149134683     PISSN: None     EISSN: 17566606     Source Type: Journal    
DOI: 10.1186/1756-6606-2-21     Document Type: Review

References (63)

1. Trinucleotide Repeat Disorders. HT Orr HJ Zoghbi, Annu Rev Neurosci 2007 30 575 621 10.1146/annurev.neuro.29.051605.113042 17417937 (Pubitemid 47218768)
2. Interacting proteins as genetics modifiers of Huntington's Disease. XJ Li M Friedman SH Li, Trends Genet 2007 23 531 533 10.1016/j.tig.2007.07.007 17961788 (Pubitemid 350052351)
3. Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain. M DiFiglia E Sapp KO Chase SW Davies GP Bates JP Vonsattel N Aronin, Science 1997 277 1990 1993 10.1126/science.277.5334.1990 9302293 (Pubitemid 27449140)
4. Nuclear and Neuropil Aggregates in Huntington's Disease: Relationship to Neuropathology. CA Gutekunst SH Li H Yi JS Mulroy S Kuemmerle R Jones D Rye RJ Ferrante SM Hersch XJ Li, J Neurosci. 1999 19 7 2522 2534 10087066
5. Neuronal intranuclear inclusions in SCA2: a genetic, morphological and immunohistochemical study of two cases. JT Pang P Giunti S Chamberlain SF An R Vitaliani T Scaravilli L Martinian NW Wood F Scaravilli O Ansorge, Brain 2002 125 656 663 10.1093/brain/awf060 11872620
6. Cytoplasmic and nuclear polyglutamine aggregates in SCA6 Purkinje cells. K Ishikawa K Owada K Ishida H Fujigasaki M Shun Li T Tsunemi N Ohkoshi S Toru T Mizutani M Hayashi N Arai K Hasegawa T Kawanami T Kato T Makifuchi S Shoji T Tanabe H Mizusawa, Neurology 2001 56 1753 1756 11425948
7. Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse. JM Ordway S Tallaksen-Greene CA Gutekunst EM Bernstein JA Cearley HW Wiener LS Dure 4th R Lindsey SM Hersch RS Jope RL Albin PJ Detloff, Cell 1997 91 753 763 10.1016/S0092-8674(00)80464-X 9413985 (Pubitemid 28007732)
8. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. CJ Cummings MA Mancini B Antalffy DB DeFranco HT Orr HY Zoghbi, Nat Genet. 1998 19 2 148 154 10.1038/502 9620770 (Pubitemid 28248795)
9. Analysis of the Role of Heat Shock Protein (Hsp) Molecular Chaperones in Polyglutamine Disease. Y Chai SL Koppenhafer NM Bonini HL Paulson, J Neurosci 1999 19 10338 10347 10575031
10. Polyglutamine neurodegeneration: protein misfolding revisited. AJ Williams HL Paulson, Trends Neurosci 2008 31 521 528 10.1016/j.tins.2008.07.004 18778858
11. Conformational changes and aggregation of expanded Polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis. Y Nagai HA Popiel, Curr Pharm Des 2008 14 3267 3279 10.2174/138161208786404164 19075705
12. Caspase Cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. CL Wellington LM Ellerby CA Gutekunst D Rogers S Warby RK Graham O Loubser J van Raamsdonk R Singaraja YZ Yang J Gafni D Bredeson SM Hersch BR Leavitt S Roy DW Nicholson MR Hayden, J Neurosci 2002 22 7862 7872 12223539
13. 2-terminal fragment complexes that are promoted by the age-dependent decrease in proteasome activity. H Zhou F Cao Z Wang ZX Yu HP Nguyen J Evans SH Li XJ Li, J Cell Biol 2003 163 109 118 14557250 10.1083/jcb.200306038 (Pubitemid 37271438)
14. Q150/Q150knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. B Woodman R Butler C Landles MK Lupton J Tse E Hockly H Moffitt K Sathasivam GP Bates, Brain Res Bull 2007 72 83 97 10.1016/j.brainresbull.2006.11.004 17352931 (Pubitemid 46367466)
15. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the Polyglutamine tract. CL Wellington LM Ellerby AS Hackam RL Margolis MA Trifiro R Singaraja K McCutcheon GS Salvesen SS Propp M Bromm KJ Rowland T Zhang D Rasper S Roy N Thornberry L Pinsky A Kakizuka CA Ross DW Nicholson DE Bredesen MR Hayden, J Biol Chem 1998 273 9158 9167 10.1074/jbc.273.15.9158 9535906 (Pubitemid 28176206)
16. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. CL Wellington R Singaraja L Ellerby J Savill S Roy B Leavitt E Cattaneo A Hackam A Sharp N Thornberry DW Nicholson DE Bredesen MR Hayden, J Biol Chem 2000 275 19831 19838 10.1074/jbc.M001475200 10770929 (Pubitemid 30441585)
17. Caspase-3 cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. YJ Kim Y Yi E Sapp Y Wang B Cuiffo KB Kegel ZH Qin N Aronin M DiFiglia, PNAS 2001 98 12784 12789 11675509 10.1073/pnas.221451398 (Pubitemid 33020022)
18. Calpain activation in Huntington's disease. J Gafni LM Ellerby, J Neurosci 2002 22 4842 4849 12077181
19. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. A Lunkes KS Lindenberg L Ben-Haem C Weber D Devys GB Landwehrmeyer JL Mandel Y Trottier, Mol Cell 2002 10 259 269 10.1016/S1097-2765(02)00602-0 12191472 (Pubitemid 35007341)
20. Nuclear localization of a non-caspase truncation product of atrophin-1, with an expanded Polyglutamine repeat, increases cellular toxicity. FC Nucifora Jr LM Ellerby CL Wellington JD Wood WJ Herring A Sawa MR Hayden VL Dawson TM Dawson CA Ross, J Biol Chem 2003 278 13047 13055 10.1074/jbc.M211224200 12464607 (Pubitemid 36800072)
21. Nuclear accumulation of truncated atrophin-1 fragments in a transgenic mouse model of DRPLA. G Schilling JD Wood K Duan HH Slunt V Gonzales M Yamada JK Cooper RL Margolis NA Jenkins NG Copeland H Takahashi S Tsuji DL Price DR Borchelt CA Ross, Neuron 1999 24 275 286 10.1016/S0896-6273(00)80839-9 10677044 (Pubitemid 29466165)
22. A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. D Goti SM Katzen J Mez N Kurtis J Kiluk L Ben-Haem NA Jenkins NG Copeland A Kakizuka AH Sharp CA Ross PR Mouton V Colomer, J Neurosci 2004 24 10266 10279 10.1523/JNEUROSCI.2734-04.2004 15537899 (Pubitemid 39492054)
23. Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3. A Haake FU Hartl P Breuer, J Biol Chem 2007 282 18851 18856 10.1074/jbc.M611914200 17488727 (Pubitemid 47100145)
24. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. SW Davies M Turmaine BA Cozens M DiFiglia AH Sharp CA Ross E Scherzinger EE Wanker L Mangiarini GP Bates, Cell 1997 90 537 548 10.1016/S0092-8674(00)80513-9 9267033 (Pubitemid 27347243)
25. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. L Mangiarini K Sathasivam M Seller B Cozens A Harper C Hetherington M Lawton Y Trottier H Lehrach SW Davies GP Bates, Cell 1996 87 493 506 10.1016/S0092-8674(00)81369-0 8898202 (Pubitemid 26374323)
26. Nuclear targeting of mutant huntingtin increases toxicity. MF Peters FC Nucifora Jr J Kushi HC Seaman JK Cooper WJ Herring VL Dawson TM Dawson CA Ross, Mol Cell Neurosci 1999 14 121 128 10.1006/mcne.1999.0773 10479410 (Pubitemid 29444882)
27. Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's Disease. CL Benn C Landles H Li AD Strand B Woodman K Sathasivam SH Li S Ghazi-Noori E Hockly SMNN Faruque JHJ Cha PT Sharpe JM Olson XJ Li GP Bates, Hum Mol Genet 2005 14 3065 3078 10.1093/hmg/ddi340 16183657 (Pubitemid 41535471)
28. II130, interfering with CREB-dependent transcription. T Shimohata T Nakajima M Yamada C Uchida O Onodera S Naruse T Kimura R Koide K Nozaki Y Sano H Ishiguro K Sakoe T Ooshima A Sato T Ikeuchi M Oyake T Sato Y Aoyagi I Hozumi T Nagatsu Y Takiyama M Nishizawa J Goto I Kanazawa I Davidson N Tanese H Takahashi S Tsuji, Nat Genet 2000 26 29 36 10.1038/79139 10973244 (Pubitemid 30692852)
29. Interference by huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity. FC Nucifora Jr M Sasaki MF Peters H Huang JK Cooper M Yamada H Takahashi S Tsuji J Troncoso VL Dawson Tm Dawson CA Ross, Science 2001 291 2423 2428 10.1126/science.1056784 11264541 (Pubitemid 32231807)
30. Interaction of Huntington disease protein with transcriptional activator Sp1. SH Li AL Cheng H Zhou S Lam M Rao H Li XJ Li, Mol Cell Biol 2002 22 1277 1287 11839795 10.1128/MCB.22.5.1277-1287.2002 (Pubitemid 34150765)
31. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. AW Dunah H Jeong A Griffin YM Kim DG Standaert SM Hersch MM Mouradian AB Young N Tanese D Krainc, Science 2002 296 2238 2243 10.1126/science.1072613 11988536 (Pubitemid 34680312)
32. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. L Cui H Jeong F Borovecki CN Parkhurst N Tanese D Krainc, Cell 2006 127 59 69 10.1016/j.cell.2006.09.015 17018277 (Pubitemid 44466642)
33. Polyglutamine domain modulates the TB-TFIIB interaction: implications for its normal function and neurodegeneration. MJ Friedman AG Shah ZH Fang EG Ward ST Warren SH Li XJ Li, Nat Neurosci 2007 10 1519 1528 10.1038/nn2011 17994014 (Pubitemid 350175880)
34. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. IA Klement PJ Skinner MD Kaytor H Yi SM Hersch HB Clark HY Zoghbi HT Orr, Cell 1998 95 41 53 10.1016/S0092-8674(00)81781-X 9778246 (Pubitemid 28458023)
35. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. F Saudou S Finkbeiner D Devys ME Greenberg, Cell 1998 95 55 66 10.1016/S0092-8674(00)81782-1 9778247 (Pubitemid 28458024)
36. Huntington aggregates may not predict neuronal death in Huntington's disease. S Kuemmerle CA Gutekunst AM Klein XJ Li SH Li MF Beal SM Hersch RJ Ferrante, Ann Neurol 1999 46 842 849
37. Transcriptional abnormalities in Huntington disease. KL Sugars DC Rubensztein, Trends Genet 2003 19 233 238 10.1016/S0168-9525(03)00074-X 12711212 (Pubitemid 36511427)
38. Mutant huntingtin's effect on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. A Kuhn DR Goldstein A Hodges AD Strand T Sengstag C Kooperberg K Becanovic MA Pouladi K Sathasiviam JH Cha AJ Hannan MR Hayden BR Leavitt SB Dunnett RJ Ferrante R Albin P Shelbourne M Delorenzi SJ Augood RLM Faull JM Olson GP Bates L Jones R Luthi-Carter, Hum Mol Genet 2007 16 1845 1861 10.1093/hmg/ddm133 17519223 (Pubitemid 47244533)
39. Subcellular localization of the Huntington's disease gene product in cell lines by immunoflourescence and biochemical subcellular fractionation. KE De Rooij JC Dorsman MA Smoor JT Den Dunnen GJ Van Ommen, Hum Mol Genet 1996 5 1093 1099 10.1093/hmg/5.8.1093 8842726
40. Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease. CE Wang S Tydlacka AL Orr SH Yang RK Graham MR Hayden SH Li AW Chan XJ Li, Hum Mol Genet 2008 17 2738 2751 10.1093/hmg/ddn175 18558632
41. Huntingtin contains a highly conserved nuclear export signal. J Xia DH Lee J Taylor M Vandelft R Truant, Hum Mol Genet 2003 12 1393 1403 10.1093/hmg/ddg156 12783847
42. The nuclear pore complex: mediator of translocation between nucleus and cytoplasm. TD Allen JM Cronshaw S Bagley E Kiseleva MW Goldberg, J Cell Sci 2000 113 1651 1659 10769196
43. In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's Disease. AS Hackam R Singaraja T Zhang L Gan MR Haydan, Hum Mol Genet 1999 8 25 33 10.1093/hmg/8.1.25 9887328 (Pubitemid 29039045)
44. Polyglutamine expansion of huntingtin impairs its nuclear export. J Cornett F Cao CE Wang CA Ross GP Bates SH Li XJ Li, Nat Genet 2005 37 198 204 10.1038/ng1503 15654337
45. Tpr, a large coiled coil protein whose amino terminus is involved in activation of oncogenic kinases, is localized to the cytoplasmic surface of the nuclear pore complex. DA Byrd DJ Sweet N Panté KN Konstantinov T Guan AC Saphire PJ Mitchell CS Cooper U Aebi L Gerace, J Cell Biol 1994 127 1515 1526 7798308 10.1083/jcb.127.6.1515 (Pubitemid 24380892)
46. Identification of protein p270/Tpr as a constitutive component of the nuclear pore complex-attached intranuclear filaments. VC Cordes S Reidenbach HR Rackwitz WW Franke, J Cell Biol 1997 136 515 529 9024684 10.1083/jcb.136.3.515 (Pubitemid 27083755)
47. Tpr is localized within the nuclear basket of the pore complex and has a role in nuclear potein export. P Frosst T Guan C Subasute K Hahn L Gerace, J Cell Biol 2002 156 617 630 11839768 10.1083/jcb.200106046 (Pubitemid 34839878)
48. Impairment of the ubiquitin-proteasome system by protein aggregation. NF Bence RM Sampat RR Kopito, Science 2001 292 1552 1555 10.1126/science.292.5521. 1552 11375494 (Pubitemid 32493425)
49. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. S Waelter A Boeddrich R Lurz E Scherzinger G Lueder H Lehrach EE Wanker, Mol Biol Cell 2001 12 1393 1407 11359930
50. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. NR Jana EA Zemskov GH Wang N Nukina, Hum Mol Genet 2001 10 1049 1059 10.1093/hmg/10.10.1049 11331615
51. Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation. AB Bowman SY Yoo NP Dantuma HY Zoghbi, Hum Mol Genet 2005 14 679 691 10.1093/hmg/ddi064 15661755 (Pubitemid 40309593)
52. Neuronal induction of the immunoproteasome in Huntington's disease. M Diaz-Hernández F Hernández E Martín-Aparicio P Gmez-Ramos MA Morán JG Castão I Ferrer J Avila JJ Lucas, J Neurosci 2003 23 11653 11661 14684867
53. Proteasome impairment does not contribute to the pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REG as a therapeutic target. JS Bett GM Goellner B Woodman G Pratt M Rechsteiner GP Bates, Hum Mol Genet 2006 15 33 44 10.1093/hmg/ddi423 16311253 (Pubitemid 43020102)
54. Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice. J Wang CE Wang A Orr S Tydlacka SH Li XJ Li, J Cell Biol 2008 180 1177 1189 18362179 10.1083/jcb.200709080
55. Differential activities of the ubiquitin-proteasome system in neurons versus glia may account for the preferential accumulation of misfolded proteins in neurons. S Tydlacka CE Wang X Wang SH Li XJ Li, J Neurosci 2008 28 13285 13295 19052220 10.1523/JNEUROSCI.4393-08.2008
56. Proteasome function in aging and oxidative stress: implications in protein maintenance failure. L Farout B Friguet, Antioxid Redox Signal 2006 8 205 216 10.1089/ars.2006.8.205 16487054 (Pubitemid 43324547)
57. Regulation of proteasome-mediated protein degradation during oxidative stress and aging. N Breusing T Grune, Biol Chem 2008 389 203 209 10.1515/BC.2008.029 18208355 (Pubitemid 351329027)
58. Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. DG Hay K Sathasivam S Tobaben B Stahl M Marber R Mestril A Mahal DL Smith B Woodman GP Bates, Hum Mol Genet 2004 13 1389 1405 10.1093/hmg/ddh144 15115766 (Pubitemid 38961645)
59. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. AL Orr SH Li CE Wang H Li J Wang J Rong X Xu PG Mastroberardino JT Greenamyre XJ Li, J Neurosci 2008 28 2783 2792 18337408 10.1523/JNEUROSCI.0106-08.2008
60. Molecular chaperones enhance the degradation of expanded polyglutamine repeat androgen receptor in a cellular model of spinal and bulbar muscular atrophy. CK Bailey IF Andriola HH Kampinga DE Merry, Hum Mol Genet 2002 11 515 523 10.1093/hmg/11.5.515 11875046
61. Chaperone suppression of cellular toxicity of huntingtin is independent of polyglutamine aggregation. H Zhou SH Li XJ Li, J Biol Chem 2001 276 48417 48424 11606565
62. Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. ES Emamian MD Kaytor LA Duvick T Zu SK Tousey HY Zoghbi HB Clark HT Orr, Neuron 2003 38 375 387 10.1016/S0896-6273(03)00258-7 12741986 (Pubitemid 36579141)
63. SUMO modification of Huntingtin and Huntington's disease pathology. JS Steffan N Agrawal J Pallos E Rockabrand LC Trotman N Slepko K Illes T Lukacsovich YZ Zhu E Cattaneo PP Pandolfi LM Thompson JL Marsh, Science 2004 304 100 104 10.1126/science.1092194 15064418 (Pubitemid 38451465)